Oncotelic Therapeutics, Inc. (OTLC)
USD 0.05
(-25.71%)
USD 0.05
(-25.71%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 30.01 Million USD | -16.89% |
| 2022 | 36.11 Million USD | 52.95% |
| 2021 | 23.61 Million USD | -0.21% |
| 2020 | 23.66 Million USD | -0.09% |
| 2019 | 23.68 Million USD | 2864.3% |
| 2018 | 799 Thousand USD | -31.83% |
| 2017 | 1.17 Million USD | -91.7% |
| 2016 | 14.11 Million USD | -48.59% |
| 2015 | 27.45 Million USD | -9.76% |
| 2014 | 30.42 Million USD | 317.1% |
| 2013 | 7.29 Million USD | 33.91% |
| 2012 | 5.44 Million USD | -50.73% |
| 2011 | 11.05 Million USD | 98.6% |
| 2010 | 5.56 Million USD | -64.35% |
| 2009 | 15.61 Million USD | -55.42% |
| 2008 | 35.03 Million USD | 16.52% |
| 2007 | 30.06 Million USD | -36.9% |
| 2006 | 47.64 Million USD | -20.95% |
| 2005 | 60.26 Million USD | 89.78% |
| 2004 | 31.75 Million USD | 57.17% |
| 2003 | 20.2 Million USD | 48.58% |
| 2002 | 13.59 Million USD | -38.62% |
| 2001 | 22.15 Million USD | -29.06% |
| 2000 | 31.22 Million USD | -26.79% |
| 1999 | 42.65 Million USD | 29.27% |
| 1998 | 33 Million USD | -19.9% |
| 1997 | 41.2 Million USD | 0.0% |
| 1996 | 41.2 Million USD | 267.86% |
| 1995 | 11.2 Million USD | 133.33% |
| 1994 | 4.8 Million USD | -36.84% |
| 1993 | 7.6 Million USD | 3700.0% |
| 1992 | 200 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 29.97 Million USD | -0.14% |
| 2024 Q2 | 29.93 Million USD | -0.13% |
| 2023 Q1 | 36.04 Million USD | -0.2% |
| 2023 FY | 30.01 Million USD | -16.89% |
| 2023 Q4 | 30.01 Million USD | -0.27% |
| 2023 Q3 | 30.09 Million USD | 0.28% |
| 2023 Q2 | 30.01 Million USD | -16.74% |
| 2022 Q1 | 23.13 Million USD | -2.04% |
| 2022 Q4 | 36.11 Million USD | -10.24% |
| 2022 FY | 36.11 Million USD | 52.95% |
| 2022 Q2 | 40.38 Million USD | 74.6% |
| 2022 Q3 | 40.23 Million USD | -0.37% |
| 2021 Q2 | 23.71 Million USD | -1.15% |
| 2021 Q1 | 23.98 Million USD | 1.37% |
| 2021 FY | 23.61 Million USD | -0.21% |
| 2021 Q3 | 23.19 Million USD | -2.2% |
| 2021 Q4 | 23.61 Million USD | 1.82% |
| 2020 Q4 | 23.66 Million USD | -3.92% |
| 2020 Q1 | 23.59 Million USD | -0.37% |
| 2020 Q2 | 24.01 Million USD | 1.77% |
| 2020 Q3 | 24.62 Million USD | 2.56% |
| 2020 FY | 23.66 Million USD | -0.09% |
| 2019 Q3 | 7.52 Million USD | -1.71% |
| 2019 Q2 | 7.65 Million USD | 1859.04% |
| 2019 FY | 23.68 Million USD | 2864.3% |
| 2019 Q4 | 23.68 Million USD | 214.59% |
| 2019 Q1 | 391 Thousand USD | -51.06% |
| 2018 FY | 799 Thousand USD | -31.83% |
| 2018 Q3 | 1.14 Million USD | -45.26% |
| 2018 Q4 | 799 Thousand USD | -30.46% |
| 2018 Q1 | 437 Thousand USD | -62.71% |
| 2018 Q2 | 2.09 Million USD | 380.32% |
| 2017 Q4 | 1.17 Million USD | -60.61% |
| 2017 FY | 1.17 Million USD | -91.7% |
| 2017 Q1 | 10.17 Million USD | -27.91% |
| 2017 Q2 | 6.52 Million USD | -35.83% |
| 2017 Q3 | 2.97 Million USD | -54.43% |
| 2016 Q3 | 17.26 Million USD | -15.5% |
| 2016 Q2 | 20.42 Million USD | -15.73% |
| 2016 FY | 14.11 Million USD | -48.59% |
| 2016 Q4 | 14.11 Million USD | -18.23% |
| 2016 Q1 | 24.24 Million USD | -11.7% |
| 2015 FY | 27.45 Million USD | -9.76% |
| 2015 Q3 | 30.73 Million USD | -8.63% |
| 2015 Q4 | 27.45 Million USD | -10.68% |
| 2015 Q1 | 36.55 Million USD | 20.16% |
| 2015 Q2 | 33.63 Million USD | -7.98% |
| 2014 Q3 | 33.25 Million USD | -9.75% |
| 2014 Q4 | 30.42 Million USD | -8.51% |
| 2014 Q2 | 36.84 Million USD | 45.95% |
| 2014 Q1 | 25.24 Million USD | 246.12% |
| 2014 FY | 30.42 Million USD | 317.1% |
| 2013 FY | 7.29 Million USD | 33.91% |
| 2013 Q4 | 7.29 Million USD | -20.9% |
| 2013 Q1 | 5.18 Million USD | -4.87% |
| 2013 Q2 | 8.3 Million USD | 60.27% |
| 2013 Q3 | 9.22 Million USD | 11.03% |
| 2012 FY | 5.44 Million USD | -50.73% |
| 2012 Q3 | 6.86 Million USD | -11.23% |
| 2012 Q4 | 5.44 Million USD | -20.68% |
| 2012 Q1 | 8.98 Million USD | -18.7% |
| 2012 Q2 | 7.73 Million USD | -13.93% |
| 2011 FY | 11.05 Million USD | 98.6% |
| 2011 Q4 | 11.05 Million USD | -17.34% |
| 2011 Q3 | 13.37 Million USD | 41.38% |
| 2011 Q2 | 9.46 Million USD | 145.65% |
| 2011 Q1 | 3.85 Million USD | -30.82% |
| 2010 FY | 5.56 Million USD | -64.35% |
| 2010 Q1 | 15.73 Million USD | 0.74% |
| 2010 Q2 | 8.66 Million USD | -44.9% |
| 2010 Q3 | 7.68 Million USD | -11.41% |
| 2010 Q4 | 5.56 Million USD | -27.51% |
| 2009 Q2 | 22.44 Million USD | -21.08% |
| 2009 Q1 | 28.43 Million USD | -18.82% |
| 2009 Q3 | 24.26 Million USD | 8.12% |
| 2009 Q4 | 15.61 Million USD | -35.65% |
| 2009 FY | 15.61 Million USD | -55.42% |
| 2008 Q4 | 35.03 Million USD | 167.19% |
| 2008 FY | 35.03 Million USD | 16.52% |
| 2008 Q1 | 24.78 Million USD | -17.58% |
| 2008 Q3 | 13.11 Million USD | -34.54% |
| 2008 Q2 | 20.02 Million USD | -19.18% |
| 2007 Q1 | 43.93 Million USD | -7.79% |
| 2007 FY | 30.06 Million USD | -36.9% |
| 2007 Q2 | 40.65 Million USD | -7.46% |
| 2007 Q3 | 35.49 Million USD | -12.7% |
| 2007 Q4 | 30.06 Million USD | -15.29% |
| 2006 Q4 | 47.64 Million USD | -5.29% |
| 2006 Q1 | 57.01 Million USD | -5.4% |
| 2006 Q2 | 53.26 Million USD | -6.58% |
| 2006 FY | 47.64 Million USD | -20.95% |
| 2006 Q3 | 50.3 Million USD | -5.55% |
| 2005 Q4 | 60.26 Million USD | 57.2% |
| 2005 Q3 | 38.33 Million USD | -4.85% |
| 2005 Q2 | 40.29 Million USD | -7.71% |
| 2005 Q1 | 43.65 Million USD | 37.48% |
| 2005 FY | 60.26 Million USD | 89.78% |
| 2004 Q3 | 34.55 Million USD | -6.85% |
| 2004 FY | 31.75 Million USD | 57.17% |
| 2004 Q1 | 40.88 Million USD | 102.33% |
| 2004 Q2 | 37.09 Million USD | -9.25% |
| 2004 Q4 | 31.75 Million USD | -8.1% |
| 2003 FY | 20.2 Million USD | 48.58% |
| 2003 Q4 | 20.2 Million USD | -9.31% |
| 2003 Q3 | 22.28 Million USD | -8.88% |
| 2003 Q2 | 24.45 Million USD | 109.01% |
| 2003 Q1 | 11.69 Million USD | -13.97% |
| 2002 Q1 | 20.41 Million USD | -7.83% |
| 2002 Q3 | 15.7 Million USD | -8.77% |
| 2002 Q2 | 17.21 Million USD | -15.7% |
| 2002 FY | 13.59 Million USD | -38.62% |
| 2002 Q4 | 13.59 Million USD | -13.4% |
| 2001 Q2 | 25.99 Million USD | -10.67% |
| 2001 FY | 22.15 Million USD | -29.06% |
| 2001 Q4 | 22.15 Million USD | -9.16% |
| 2001 Q1 | 29.09 Million USD | -6.82% |
| 2001 Q3 | 24.38 Million USD | -6.18% |
| 2000 Q1 | 40.03 Million USD | -6.15% |
| 2000 Q3 | 34.01 Million USD | -7.81% |
| 2000 Q4 | 31.22 Million USD | -8.19% |
| 2000 Q2 | 36.89 Million USD | -7.84% |
| 2000 FY | 31.22 Million USD | -26.79% |
| 1999 FY | 42.65 Million USD | 29.27% |
| 1999 Q1 | 31.2 Million USD | -5.45% |
| 1999 Q2 | 28.6 Million USD | -8.33% |
| 1999 Q3 | 24.8 Million USD | -13.29% |
| 1999 Q4 | 42.65 Million USD | 72.02% |
| 1998 Q3 | 36 Million USD | -4.26% |
| 1998 FY | 33 Million USD | -19.9% |
| 1998 Q1 | 39.8 Million USD | -3.4% |
| 1998 Q2 | 37.6 Million USD | -5.53% |
| 1998 Q4 | 33 Million USD | -8.33% |
| 1997 FY | 41.2 Million USD | 0.0% |
| 1997 Q2 | 43.3 Million USD | 0.0% |
| 1997 Q4 | 41.2 Million USD | -5.29% |
| 1997 Q3 | 43.5 Million USD | 0.46% |
| 1997 Q1 | 43.3 Million USD | 5.1% |
| 1996 Q4 | 41.2 Million USD | 221.88% |
| 1996 Q3 | 12.8 Million USD | 17.43% |
| 1996 FY | 41.2 Million USD | 267.86% |
| 1996 Q2 | 10.9 Million USD | 0.93% |
| 1996 Q1 | 10.8 Million USD | -3.57% |
| 1995 Q2 | 2.9 Million USD | -25.64% |
| 1995 Q1 | 3.9 Million USD | -18.75% |
| 1995 Q4 | 11.2 Million USD | 0.0% |
| 1995 FY | 11.2 Million USD | 133.33% |
| 1994 Q2 | 6.5 Million USD | 0.0% |
| 1994 Q4 | 4.8 Million USD | 0.0% |
| 1994 FY | 4.8 Million USD | -36.84% |
| 1993 Q3 | 7.6 Million USD | 0.0% |
| 1993 FY | 7.6 Million USD | 3700.0% |
| 1993 Q4 | 7.6 Million USD | 0.0% |
| 1992 FY | 200 Thousand USD | 0.0% |
| 1992 Q4 | 200 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -1299248.571% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1432.791% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -184.394% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -5336.309% |
| Rebus Holdings, Inc. | 5000.00 USD | -600199.04% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 76.949% |
| Qrons Inc. | 420.00 USD | -7146317.143% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -3794.788% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -7.411% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -6145.867% |
| Skye Bioscience, Inc. | 11.94 Million USD | -151.373% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 22.735% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -315.733% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -39210.255% |
| SQZ Biotechnologies Company | 107.18 Million USD | 71.998% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1995.969% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -41377.167% |
| Mesoblast Limited | 667.9 Million USD | 95.506% |
| Marizyme, Inc. | 22.01 Million USD | -36.338% |
| Genus plc | 1.02 Billion USD | 97.083% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -2109.658% |
| Pharming Group N.V. | 462.85 Million USD | 93.515% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -805.972% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -5914.55% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -4687.074% |
| ContraFect Corporation | 20.67 Million USD | -45.147% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -7588.926% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -7753.678% |
| IMV Inc. | 31.33 Million USD | 4.209% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -623.946% |
| MultiCell Technologies, Inc. | 126.22 USD | -23779770.068% |
| ONE Bio Corp. | 70.08 Million USD | 57.174% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -3094.137% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 76.644% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -6852.508% |
| Q BioMed Inc. | 3.51 Million USD | -753.785% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 14.679% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -11387.79% |
| Biomind Labs Inc. | 73.81 Thousand USD | -40560.199% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 93.275% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1971.65% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -992.909% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -4265.9% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1053.004% |
| GB Sciences, Inc. | 103.44 Thousand USD | -28916.214% |
| Alpha Cognition Inc. | 2.45 Million USD | -1124.016% |
| HST Global, Inc. | 1526.00 USD | -1966803.801% |
| CSL Limited | 38.02 Billion USD | 99.921% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -2938.052% |
| Halberd Corporation | 10.13 Thousand USD | -296168.404% |
| Enzolytics Inc. | 361.7 Million USD | 91.702% |
| Agentix Corp. | 261.39 Thousand USD | -11382.736% |
| Resverlogix Corp. | 8.11 Million USD | -269.87% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1498.342% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.339% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 37.078% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -4592.358% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -131654.322% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -235.394% |
| AVAX Technologies, Inc. | 7.37 Million USD | -306.863% |
| Zenith Capital Corp. | 7410.00 USD | -404960.081% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.114% |
| Ember Therapeutics, Inc. | 184.00 USD | -16312373.913% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -9227.033% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -11383.966% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -3134.506% |
| Kadimastem Ltd | 2.3 Million USD | -1202.687% |
| Helix BioMedix, Inc. | 3.02 Million USD | -892.202% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 43.047% |
| BioStem Technologies, Inc. | 14.56 Million USD | -106.143% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -52471.114% |
| LadRx Corporation | 2.3 Million USD | -1200.541% |
| Cell Source, Inc. | 195.17 Thousand USD | -15278.797% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -8387.983% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -8387.983% |
| NovAccess Global Inc. | 62.24 Thousand USD | -48118.34% |
| Affymax, Inc. | 7.44 Million USD | -303.264% |
| Itoco Inc. | 1.4 Million USD | -2043.815% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -31277.685% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -28215.992% |
| Mobile Lads Corp. | 52.00 USD | -57720961.538% |
| CytoDyn Inc. | 11.13 Million USD | -169.531% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -20893.588% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -167768.859% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -7686.566% |
| SYBLEU INC | 330.46 Thousand USD | -8982.559% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -7231.055% |
| International Stem Cell Corporation | 5.39 Million USD | -456.864% |
| Bioxytran, Inc. | 137.63 Thousand USD | -21707.17% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -100.075% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -81.042% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -37893.61% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -3371.233% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -299.294% |
| Neutra Corp. | 2851.00 USD | -1052686.812% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 7.378% |
| PureTech Health plc | 693.97 Million USD | 95.675% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -271.882% |
| IXICO plc | 15.84 Million USD | -89.442% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -262.412% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 70.951% |
| CSL Limited | 38.02 Billion USD | 99.921% |
| Cellectis S.A. | 333.99 Million USD | 91.013% |